Transparent Labs Shutdown: The 90-Day Aftermath and What It Taught Researchers

When Transparent Labs paused new orders in late February 2026, the peptide-research community reacted in roughly the way you would expect a market with no FDA backstop to react: panic-buying, forum speculation, and a frantic search for "next-best" alternatives. Ninety days later, the picture is clearer. Most displaced customers settled with one of four replacement vendors, prices on the most-impacted SKUs rose modestly, and the episode produced a small library of cautionary threads on r/Peptides about vendor concentration risk. This post is a retrospective: what happened, where the demand went, and what researchers should change about their sourcing process.

We are not breaking news here. We are looking back at three months of community signal and asking what the shutdown should change about how a careful researcher evaluates a vendor in the first place.

What Transparent Labs Was#

Transparent Labs operated as a US-domestic gray-market peptide vendor with a catalog that overlapped heavily with the standard set: GLP-1 receptor agonists, healing peptides, growth-hormone secretagogues, and a handful of melanocortin and cognitive compounds.¹ Its appeal — at least according to community testimony on the r/Peptides and Excel Male forums — was a combination of moderate pricing, reasonably fast US shipping, and a published policy of third-party HPLC testing on at least some product lines.

It was never the largest vendor in the space and it was never the cheapest. It occupied a middle-of-the-distribution niche that, in retrospect, was probably the most exposed segment of the market: large enough to attract regulatory attention, small enough to lack a contingency plan, and priced just high enough that switching costs felt non-trivial to repeat customers.

Timeline of the Shutdown#

The publicly verifiable timeline is sparse. Most of what the community knows comes from forum threads and direct customer reports.

• Late February 2026: New order placement reportedly began returning errors or "out of stock" on most SKUs across the catalog.
• Early March 2026: Customers reported that existing-order tracking still worked but no new shipments were leaving the warehouse.
• Mid-March through May 2026: The storefront remained reachable but order placement remained disabled; community moderators on multiple peptide forums updated their pinned vendor lists to flag Transparent Labs as inactive. Details of the precipitating event (regulatory action, banking/payment-processor termination, voluntary closure, or operational failure) were never publicly confirmed.

The information vacuum is itself part of the case study. Gray-market vendors rarely issue shutdown statements. There is no press release, no court filing, and no FDA Form 483 to subpoena. What you get is an empty cart page, eventually a 404, and a backlog of forum threads where customers compare notes about whether their last order shipped.

Where the Customer Base Went#

By the end of May 2026, the community migration appears to have concentrated around four vendors. The signal here is forum-thread density on r/Peptides and the Excel Male and PSL forums; it is not a clean dataset, and we have not tried to triangulate it with paid search-trend tooling.

Core Peptides (Orlando, FL)#

Core Peptides absorbed a noticeable share of the displaced demand. The vendor's appeal in this context was operational rather than reputational: same-day USPS shipping, the widest payment-method support in the segment (credit card, Venmo, Zelle, CashApp, crypto, ACH), and a 30-day refund window.² On our 8-dimension vendor scoring framework, Core Peptides lands at roughly 7.5 weighted overall, with payment flexibility (9) and shipping speed (8.5) carrying the score and COA transparency (7) and pricing (6) dragging it down.

The COA caveat matters here. Core Peptides publishes third-party testing on parts of the catalog but not consistently across SKUs, and COAs are not always included with shipments.² For displaced Transparent Labs customers who had grown used to a tested product, the move was partial — they got the shipping speed but accepted some downgrade in COA accessibility.

AminoVault#

AminoVault became the second large beneficiary, particularly for researchers focused on the broader healing and growth-hormone secretagogue categories rather than GLP-1s. Community discussion on r/Peptides through April and May referenced AminoVault as a "rebuild after Transparent" choice in several threads.

Felix Chemical Supply#

Felix Chemical Supply picked up share among customers who prioritized published HPLC data. The migration here was smaller in absolute numbers but concentrated in researchers who explicitly cited COA quality as the reason they were not willing to go to Core Peptides.

Testides (Lab-Direct)#

Testides is structurally different — it is a lab-affiliated direct-purchase platform rather than a pure resale vendor. A subset of Transparent Labs' more sophisticated customer base used the shutdown as an opportunity to move up-stream and order from a platform with in-house testing. Forum reports describe this as a quality-driven migration rather than a price-driven one.

Vendor Concentration Risk: The Real Lesson#

The most useful framing of the Transparent Labs shutdown is not "another vendor died" — it is "the median customer had no documented backup." Across three months of forum discussion, the single most common pattern in the migration threads was the same complaint, repeated by dozens of distinct posters: "I'd been ordering from Transparent for two years, never looked elsewhere, and now I'm starting from zero."

This is vendor concentration risk. It is the same operational failure mode that breaks supply chains in regulated industries, just compressed into a single-customer unit of analysis. If your research depends on a continuous supply of a specific compound and you have only one source, your practical research timeline is bounded by the lifetime of that source, not by your protocol.

The mitigation is structural, not heroic:

1. Keep two vendor relationships open at all times. Place at least one small order per quarter with your secondary so the account stays active and you have recent shipping data.
2. Cap inventory at roughly 90 days. Holding more than that compounds the loss if the vendor exits — Transparent Labs customers with six-month stockpiles still ended up sourcing replacements before they were done with their current supply, because they could not verify the remaining vials against a fresh COA.
3. Verify against an independent lab. Reputable independent testing — Janoshik Analytical is the community-consensus reference — lets you confirm identity and purity of inventory you already hold and gives you a baseline for evaluating any replacement vendor's product.³
4. Document your protocol off the vendor's site. If your dosing schedule, vial-log, and reconstitution math live only in a vendor's customer dashboard, you lose them when the vendor does. Our Protocol Builder tool exists exactly for this — local, exportable, and not dependent on any vendor staying online.

How to Re-Evaluate a Replacement Vendor#

For displaced customers who have not yet settled, the diligence checklist that came out of the Transparent Labs aftermath is shorter than most people expect. The vendors that retained customers through this episode shared three traits: published COAs you can actually open, payment-method diversity (so a single processor termination cannot end the business), and a track record of at least two years of community presence.

Use our Vendor directory to filter by company type, payment methods, and COA practice; the Beginner Guide tool walks first-time switchers through the same evaluation steps. For displaced GLP-1 customers specifically, the GLP-1 Cost Comparison post covers pricing tradeoffs across the surviving vendor set.

The Information Vacuum Problem#

One last observation. The most uncomfortable thing about writing a "90-day aftermath" piece is how much of the underlying story is still not documented. We do not know with confidence why Transparent Labs stopped taking orders. We do not have a court filing, a regulatory letter, or a statement from the operators. Most of what the community believes is reconstructed from forum sentiment and the absence of a working order page.

This is the structural condition of a gray market. Researchers who treat vendor-survival like a solved problem — picking one supplier, locking in autoship, and assuming continuity — are not doing themselves a favor. The Transparent Labs shutdown is the third comparable vendor exit in the last 18 months. There will be a fourth. The question is whether your sourcing plan survives it.

References#

Related Reading#

• Best Peptide Vendors 2026
• Finnrick Analytics Transparency Concerns
• GLP-1 Cost Comparison 2026
• Compounding Pharmacy Peptides 2026
• Janoshik Analytical Review

Footnotes#

1. Transparent Labs vendor profile (archived). Live storefront formerly at transparentlabs domain; current status: order placement disabled as of February 2026. ↩

2. Peptide Protocol Wiki. Core Peptides vendor profile. Available at: /vendors/core-peptides. Accessed June 2026. Vendor self-reported payment methods, shipping policy, and refund window confirmed against current storefront. ↩ ↩²

3. Peptide Protocol Wiki. Janoshik Analytical lab profile. Available at: /labs/janoshik-analytical. Community-consensus reference for independent peptide HPLC testing as of 2026. ↩